The Norwegian Trial of Physical Exercise After Myocardial Infarction
Launched by NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY · Oct 30, 2020
Trial Information
Current as of July 23, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Hospitalized in a Norwegian hospital with an acute myocardial infarction (Type I) during 2013-2022. Patients are included minimum 3 months after hospitalization when they are in a stable clinical condition.
- • 2. Norwegian national identification number
- • 3. Able to communicate in Norwegian or other Scandinavian language
- • 4. Being able to be physically active according to study protocol, as determined by study personnel.
- • 5. Signed informed consent.
- Exclusion criteria:
- • 1. Persons who already participate in physical activity at a similar or higher level than what is prescribed for the intervention group, as determined by study personnel.
- • 2. Participating or plans to participate in endurance sport competitions.
- • 3. Expected to emigrate during the study
- • 4. Cognitive impairment/dementia.
- • 5. Alcohol or drug abuse, or serious psychiatric disease.
- • 6. Known cardiac disease that may represent a contraindication for moderate or high-intensity physical activity, such as symptomatic valvular heart disease, hypertrophic cardiomyopathy, uncontrolled hypertension, in-compensated heart failure, serious arrythmia not under control after treatment, pulmonary hypertension, significant angina after revascularization and optimal drug treatment.
- • 7. Renal insufficiency requiring dialysis.
- • 8. Any end-stage somatic disease with short life expectancy or that is expected to interfere with the participants' ability to comply with the study protocol, such as advanced cancer, chronic lung disease with exacerbations, or other disease, as determined by study personnel.
- • 9. Inability to comply with the study protocol due to any physical disability, somatic disease or mental problem, as determined by study personnel.
- • 10. Residing in nursing home or other institution.
- • 11. Participation in another trial with exercise as an intervention modality.
About Norwegian University Of Science And Technology
The Norwegian University of Science and Technology (NTNU) is a leading research institution dedicated to advancing knowledge and innovation in various scientific fields. Renowned for its commitment to interdisciplinary collaboration, NTNU plays a pivotal role in addressing global health challenges through rigorous clinical trials and research initiatives. The university's emphasis on cutting-edge technology and its strong partnerships with healthcare sectors position it as a key player in translational research, ensuring that findings contribute effectively to improving public health and patient care. With a focus on ethical standards and scientific integrity, NTNU is dedicated to fostering advancements that enhance the quality of life and health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Trondheim, , Norway
Patients applied
Trial Officials
Øystein Risa
Study Director
Norwegian University of Science and Technology
Kaare Bønaa, MD prof
Principal Investigator
Norwegian University of Science and Technology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials